Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | IL1B | P01584 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388738 | 0.94 | POLB (0.43) | SMN1; SMN2POLBIL1BGAARXFP1 | |
| SCHEMBL6504082 | 0.86 | MEN1 (0.39) | POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL6429092 | 0.85 | PARP1 (0.33) | EPHX2 | |
| SCHEMBL6503577 | 0.84 | ALDH1A1 (0.34) | SMN1; SMN2LMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL6392731 | 0.83 | EPHX2 (0.33) | EPHX2ALDH1A1IL1B | |
| SCHEMBL14440562 | 0.83 | NAMPT (0.39) | SMN1; SMN2RAB9ANPC1POLBKMT2A | |
| SCHEMBL6498589 | 0.83 | KEAP1 (0.35) | EPHX2GAA | |
| SCHEMBL6506781 | 0.83 | P2RX7 (0.39) | SMN1; SMN2RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL6427119 | 0.82 | PPARD (0.38) | LMNAEPHX2GAA | |
| SCHEMBL6429803 | 0.81 | RAB9A (0.38) | SMN1; SMN2LMNARAB9ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | SMN1; SMN2 3733/4885LMNA 1964/4885RAB9A 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.